TD Cowen Upgrades Freenome (NASDAQ:FRNM) to “Strong-Buy”

Freenome (NASDAQ:FRNM) was upgraded by stock analysts at TD Cowen to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

FRNM has been the subject of several other reports. Jefferies Financial Group assumed coverage on shares of Freenome in a report on Monday. They issued a “buy” rating and a $17.00 target price for the company. BTIG Research began coverage on Freenome in a research note on Monday. They set a “buy” rating and a $17.00 price target for the company. Finally, Leerink Partners initiated coverage on Freenome in a report on Friday, August 14th. They issued an “outperform” rating and a $18.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company. According to data from MarketBeat, Freenome currently has a consensus rating of “Buy” and an average target price of $17.25.

Freenome Stock Performance

Shares of NASDAQ FRNM opened at $13.63 on Tuesday. Freenome has a 1 year low of $9.97 and a 1 year high of $14.26.

About Freenome

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.